In a recent interview with Dr. Adil Ali of Onyx Newsroom, Dr. Jeffery Talbot, Vice President for Research at Roseman University of Health Sciences, discussed the rapid growth of Roseman Bioventures, the changing geography of the life sciences industry, and why Las Vegas is increasingly attractive to biotechnology, medical device and other life sciences companies.

A New Model for Life Sciences Growth

Since formally launching in March, Roseman Bioventures is approaching 10 resident companies or those nearing execution, with nearly a dozen additional companies in its pipeline. Talbot explained that much of that interest is coming from companies outside Southern Nevada that are looking for more capital-efficient ways to conduct research, development and manufacturing.

Rather than attempting to replace established life sciences hubs such as Boston, San Diego or the San Francisco Bay Area, Roseman Bioventures offers companies a complementary model. Companies can maintain connections, leadership and resources in traditional hubs while establishing R&D, manufacturing or other operations in Southern Nevada.

Roseman Bioventures’ 120,000-square-foot facility provides dedicated laboratory and office space capable of supporting companies ranging from early-stage startups to more established ventures preparing to scale. Talbot told Onyx that companies comparing costs have reported that they can operate at Roseman Bioventures for significantly less than they would spend in a traditional coastal biotech hub.

The interview also highlights several companies already demonstrating this distributed model, including VenaVitals, which originated at UC Irvine and brought its R&D and manufacturing operations to Roseman Bioventures while initially maintaining its executive leadership in Southern California. Talbot also discussed companies coming to Las Vegas from New Jersey and Georgia, as well as homegrown ventures emerging from UNLV.

Becoming “The First Vegas”

Perhaps the interview’s most compelling message is that Southern Nevada doesn’t need to replicate another life sciences market to succeed.

As Talbot explains, the goal isn’t necessarily for Las Vegas to become the next San Francisco, Boston or San Diego. Instead, the opportunity is to build something uniquely suited to the region — leveraging Nevada’s business environment, proximity to California, accessibility, available infrastructure and growing network of researchers, entrepreneurs, investors and economic development partners.

“I think the ambition is to become the first Vegas,” Talbot told Onyx.

That vision is at the heart of Roseman Bioventures: creating an environment where innovative companies can stretch their capital further, access the resources they need to grow and become part of a developing life sciences ecosystem in Southern Nevada.

Read Dr. Adil Ali’s full interview with Dr. Jeffery Talbot:
“The ambition is to become the first Vegas” — Onyx Newsroom